Reviewing the regulatory barriers for nanomedicine: global questions and challenges

Nanomedicine will play an increasing role in prevention and treatment across the entire healthcare spectrum. However, their precise market size, economic value and areas of application remain unclear. This opacity, including the question of what constitutes nanomedicine matters, especially when cons...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine (London, England) England), 2015-11, Vol.10 (21), p.3275-3286
Main Authors: Bowman, Diana M, Gatof, Jake
Format: Article
Language:English
Subjects:
Cancer therapies
Chemotherapy
Drug delivery systems
Drugs
EU
FDA approval
global challenges
governance
health and safety
innovation
intellectual property
Internationality
Medical equipment
Nanomaterials
Nanomedicine
Nanoparticles
regulation
Regulatory approval
Stakeholders
USA
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nanomedicine will play an increasing role in prevention and treatment across the entire healthcare spectrum. However, their precise market size, economic value and areas of application remain unclear. This opacity, including the question of what constitutes nanomedicine matters, especially when considered alongside the key regulatory questions and concerns. This article begins by placing these key questions into context in relation to the current scientific state of the art, focusing particular attention on the human health and safety context. In exploring these central questions surrounding the regulation of nanomedicine, this perspective also explores existing and suggested frameworks that aim to deal with emerging technologies more generally. It then outlines priority areas for action and general conclusions specific to nanomedicine.
ISSN:1743-5889
1748-6963
DOI:10.2217/nnm.15.169